CTA
MDCO

Carillon Tower Advisers’s Medicines Co MDCO Stock Holding History

Carillon Tower Advisers’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-558,810
Closed -$15.3K – 483
2017
Q4 		$15.3K Buy
+558,810
New +$17.2M 0.16% 193

Other funds holding MDCO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Carillon Tower Advisers's MDCO Position: Q1 2018 in Review

Carillon Tower Advisers sold out of Medicines Co (MDCO) in Q1 2018, closing a stake of 558,810 shares — an estimated $15.3K sold.

Carillon Tower Advisers first reported a position in MDCO in Q4 2017 and held it in 1 quarter. The position peaked at $15.3K in Q4 2017. 190 funds tracked by Wall St. Rank hold MDCO as of Q1 2018.

  • Carillon Tower Advisers reported no remaining Medicines Co position as of Q1 2018 after selling out during the quarter.
  • Carillon Tower Advisers sold 558,810 Medicines Co shares in Q1 2018, an estimated $15.3K.
  • Carillon Tower Advisers first reported a position in Medicines Co in Q4 2017 and held it in 1 quarter.
  • Carillon Tower Advisers's Medicines Co position peaked at $15.3K in Q4 2017.
  • 190 funds tracked by Wall St. Rank held Medicines Co as of Q1 2018.

Based on Carillon Tower Advisers's 13F filing for Q1 2018, filed 14 May 2018.